Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat.
Yali GaoFei LiXin NiSiwang YangHan LiuXingye WuJie-Qing LiuJunjie MaPublished in: RSC advances (2023)
Herein, a series of 4-(benzofuran-6-yloxy)quinazoline derivatives as VEGFR-2/HDAC dual inhibitors were designed and synthesized based on fruquintinib and vorinostat. Among them, compound 13 exhibited potent inhibitory activity against VEGFR-2 and HDAC1 with IC 50 values of 57.83 nM and 9.82 nM, and displayed moderate to significant antiproliferative activity against MCF-7, A549, HeLa and HUVEC. The cellular mechanism studies revealed that compound 13 arrested the cell cycle at the S and G2 phases, and induced significant apoptosis in HeLa cells. Tube formation assay in HUVECs demonstrated that 13 had a significant anti-angiogenic effect. Additionally, a molecular docking study supported the initial design strategy. These results highlighted that 13 was a valuable VEGFR-2/HDAC dual inhibitor and deserved further study for cancer therapy.
Keyphrases
- histone deacetylase
- cell cycle arrest
- cell cycle
- molecular docking
- cancer therapy
- vascular endothelial growth factor
- cell death
- cell proliferation
- photodynamic therapy
- oxidative stress
- molecular dynamics simulations
- drug delivery
- pi k akt
- high throughput
- endoplasmic reticulum stress
- endothelial cells
- signaling pathway
- high intensity